Fexuclue for Prevention of NSAIDs-Induced Peptic Ulcer in Real-World Practice
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age19+
SponsorDaewoong Pharmaceutical Co. LTD.
About this trial
This study is a prospective, multi-center, observational study to evaluate the efficacy and safety of Fexuclue Tablet 20 mg in patients requiring prevention of NSAIDs-induced peptic ulcer in real-world clinical practice in Korea.
Patients receiving NSAIDs and requiring gastroprotective therapy will be enrolled and followed prospectively. The study will assess patient-reported outcomes (PROs) related to gastrointestinal symptoms, as well as safety outcomes.
Eligibility criteria
Qualifiers
Adults aged ≥19 years
Patients requiring NSAIDs therapy
Patients requiring prevention of NSAIDs-induced peptic ulcer
Patients prescribed Fexuclue Tablet 20 mg
Disqualifiers
Hypersensitivity to Fexuclue or its components
Severe hepatic impairment
Pregnant or breastfeeding women
Patients considered inappropriate by investigator
Trial design
Treatments tested in this trial
- Not listed
Trial groups
7,000 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov